<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="385">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 08, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01138930</url>
  </required_header>
  <id_info>
    <org_study_id>berberine2010</org_study_id>
    <nct_id>NCT01138930</nct_id>
  </id_info>
  <brief_title>Effect of Berberine on Hormonal and Metabolic Features in Obese Women With Polycystic Ovary Syndrome (PCOS)</brief_title>
  <official_title>Effect of Berberine on Hormonal and Metabolic Features in Obese Women With PCOS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heilongjiang University of Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heilongjiang University of Chinese Medicine</source>
  <oversight_info>
    <authority>China: Ministry of Health</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Berberine has showed effective in lowering blood sugar levels in db/db mice and
      anti-dyslipidemia in human.Studies on the effect of berberine on metabolic and hormonal
      features of women with polycystic ovary syndrome (PCOS) are lacking.The objective of this
      study is to examine the effect of Berberine metabolic and hormonal parameters and insulin
      resistance in obese patients with PCOS.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Anticipated">June 2013</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Whole body insulin action</measure>
    <time_frame>3  months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Glucose Disposal Rate measured by hyperinsulinemic euglycemic clamp</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oral glucose tolerance test (OGTT)</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ovarian androgen biosynthesis</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hormonal profile</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting lipid metabolic profile</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal and liver function tests</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6) Weight, waist/hip circumference, blood pressure, F-G score and acne before and after treatment.</measure>
    <time_frame>Three months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Berberine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Berberine</intervention_name>
    <description>1.5g daily for 3 month</description>
    <arm_group_label>Berberine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Age of women between 18 and 35 years.

          2. Confirmed diagnosis of PCOS according to the modified Rotterdam criteria and all
             subjects must have anovulation plus either polycystic ovaries and/or
             hyperandrogenism.

          3. Body mass index (BMI) equal to or greater than 23 kg/m2.

          4. With no desire of children within 6 month. PCOS is defined by the modified Rotterdam
             criteria: oligomenorrhea or amenorrhea, together with presence of ≥12 antral
             follicles (≤9mm) and/or ovarian volume &gt;10 ml on transvaginal scanning, and/or
             clinical/biochemical hyperandrogenism. Oligomenorrhea is defined as an intermenstrual
             interval &gt;35 days and &lt;8 menstrual bleedings in the past year. Amenorrhea is defined
             as an intermenstrual interval &gt;90 days. Clinical hyperandrogenism in China Mainland
             is defined as a Ferriman-Gallwey (FG) score ≥5.

        Exclusion criteria are

          1. Use of hormonal drugs or other medications including Chinese Herbal prescriptions in
             the past 3 months.

          2. Patients with other endocrine disorders including 21-hydroxylase deficiency,
             hyperprolactinemia, uncorrected thyroid disease, suspected Cushing's syndrome

          3. Patients with known sever organ dysfunction or mental illness.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lihui Hou, MD.</last_name>
    <role>Study Chair</role>
    <affiliation>The First Affliated Hospital,Heilongjiang University of Chinese Medicine .</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiaoke Wu, MD.PhD.</last_name>
    <role>Study Chair</role>
    <affiliation>The First Affliated Hospital,Heilongjiang University of Chinese Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaoke Wu, MD.PhD.</last_name>
    <phone>86-451-8213 0094</phone>
    <email>xiaokewu2002@vip.sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lihui Hou, MD.</last_name>
    <phone>86-451-8213 0094</phone>
    <email>houlihui2007@sina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Affiliated Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongxia Ma, MD</last_name>
    </contact>
    <investigator>
      <last_name>Hongxia Ma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Obstetrics and Gynecology,First Affliated Hospital,Heilongjiang University of Chinese Medicine .</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoke Wu, MD.PhD.</last_name>
      <phone>86-451-8213 0094</phone>
      <email>xiaokewu2002@vip.sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>First Affliated Hospital of Harbin Medical University</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhuoran Wang, MD</last_name>
    </contact>
    <investigator>
      <last_name>Zhuoran Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Forth Affiliated Hospital of Harbin Medcal University</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shiyu Han, MD</last_name>
    </contact>
    <investigator>
      <last_name>Shiyu Han, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 8, 2013</lastchanged_date>
  <firstreceived_date>June 7, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Heilongjiang University of Chinese Medicine</investigator_affiliation>
    <investigator_full_name>Xiaoke Wu</investigator_full_name>
    <investigator_title>Professor and Chairman Dept Obs &amp; Gyn, First Affiliated Hospital</investigator_title>
  </responsible_party>
  <keyword>Polycystic Ovary Syndrome</keyword>
  <keyword>Obesity</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
